A PHASE 3, INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF THE 9VHPV VACCINE, A MULTIVALENT L1 VIRUS-LIKE PARTICLE VACCINE, IN THE PREVENTION OF ORAL PERSISTENT INFECTION WITH HPV TYPES 16, 18, 31, 33, 45, 52, OR 58 IN ADULT MALES, 20 TO 45 YEARS OF AGE.
- Conditions
- -C760 Head, face and neckHead, face and neckC760
- Registration Number
- PER-045-19
- Lead Sponsor
- Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co. Inc.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Is healthy and is judged to be in good physical health based on medical history and physical examination.
2. Is male, from 20 years to 45 years of age inclusive, at the time of signing the informed consent.
3. Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.
4. Agrees to provide study personnel with a primary telephone number as well as an alternate means of contact, if available (such as an alternate telephone number or e- mail) for follow-up purposes.
5. Can read, understand, and complete the eVRC.
6.Has had at least 1 lifetime sexual partner.
Please refer to the protocol for more information.
1. Has a history of HPV-related anal lesion (anal intraepithelial neoplasia or anal cancer) or HPV-related head and neck cancer.
2. Has a history of or clinical evidence at the Day 1 external genital examination of HPV-related external lesion (condyloma acuminata, penile intraepithelial neoplasia or penile cancer).
3. Has clinical evidence at the Day 1 external genital examination of gross genital lesion suggesting sexually transmitted disease.
4. Has a fever (defined as oral temperature ≥100.0°F or ≥37.8°C) within the 24-hour period prior to the Day 1 visit.
5. Has a history of severe allergic reaction (eg, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention.
6. Is allergic to any vaccine component, including aluminum, yeast, or BENZONASETM (nuclease, Nycomed [used to remove residual nucleic acids from this and other vaccines]). For this exclusion criterion, an allergy to vaccine components is defined as an allergic reaction that met the criteria for severe AEs or SAEs defined in Appendix 3.
7. Has known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
8. Is currently immunocompromised or has been diagnosed as having congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition.
9. Has a history of splenectomy.
10. Has a history or current evidence of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with the participant’s participation for the full duration of the study, such that it is not in the best interest of the participant to participate by judgement of investigator.
11. Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence at the discretion of the investigator. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems because of alcohol use.
12. Has received within 12 months prior to enrollment, is receiving, or plans to receive during Day 1 through Month 7 of the study, the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (AravaTM), TNF-α antagonists, monoclonal antibody therapies (including rituximab [Rituxan™]), IVIG, antilymphocyte sera, or other therapy known to interfere with the immune response. Regarding systemic corticosteroids, a participant will be excluded if he is currently receiving steroid therapy, has recently (defined as within 2 weeks of Day 1 vaccination) received such therapy, or has received 2 or more courses of high-dose corticosteroids (≥20 mg/day of prednisone [or equivalent] orally or parenterally) lasting at least 1 week in duration in the year prior to Day 1 vaccination. Participants using inhaled, nasal, or topical steroids are considered eligible for the study.
13. Has received within the 3 months prior to the Day 1 vaccination, is receiving, or plans to receive during Day 1 through Month 7 of the study, any immune globulin product (including RhoGAM™ [Ortho-Clinical Diagnostics]) or blood-derived product other than I
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method